Search

Displaying results 981 - 990 of 6198 in total
  1. Drug

    Doxazosin

    go.drugbank.com/drugs/DB00590
    ApprovedInvestigational

    [A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285] … Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension.

  2. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels. … [A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout.

  3. Drug

    Natural Killer Cell

    go.drugbank.com/drugs/DB15721
    Investigational

    Other techniques involve using umbilical cord blood (UCB) directly; these NK cells have heterogeneous CD56 expression but are considered suitable for immunotherapy. … NK Cells express features of innate immune responses, and respond to all molecules that appear to be foreign to the body.

    Synonyms: NK Cells
  4. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

    Mixtures: Hae Yan Tooth
  5. Drug

    Arbutamine

    go.drugbank.com/drugs/DB01102
    Approved

    Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in

  6. Drug

    NADH

    go.drugbank.com/drugs/DB00157
    ApprovedNutraceutical

    It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). … NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.

  7. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    [A177709] Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization … [A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM.

  8. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret.

  9. Drug

    Flumazenil

    go.drugbank.com/drugs/DB01205
    ApprovedInvestigational

    Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine

  10. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer.